【摘要】 目的 :应用华法林对非瓣膜病性心房颤动患者进行抗凝治疗 ,观察其抗栓疗效和安全性。方法 :将非瓣膜病性心房颤动患者 117例应用华法林分进行抗凝治疗并为两组 :抗凝强度国际标准化比率 (INR) 1.6～ 2 .4组 ,6 7例 ;INR2 .5～ 3.5组 ,5 0例。观察两组血栓栓塞并发症及出血等不良反应的发生率。结果 :INR1.6～ 2 .4组血栓栓塞年发生率为 0 .75 % ,INR2 .5～ 3.5组为 0 ,两组比较差异无显著性 (P >0 .0 5 )。两组病例中 94 %的不良反应为出血 ,INR1.6～ 2 .4组出血不良反应的年发生率为 6 .9% ,INR2 .5～ 3.5组为 16 .2 % ,两组比较差异有显著性 (P <0 .0 5 ) ,但两组中均无一例为严重出血。其他不良反应为皮疹和消化道症状。结论 :华法林抗凝强度INR1.6～ 3.5时能明显降低非瓣膜病性心房颤动患者血栓栓塞的发生率 ,其安全性好。INR1.6～ 2 .4时有一定的血栓栓塞危险 ,INR2 .5～3.5时有一定的严重出血危险性。更多还原

【Abstract】 Objective: To observe the antithrombotic effect and safety of warfarin in the anticoagulant therapy for patients with nonvalvular atrial fibrillation. Methods: 117 patients with nonvalvular atrial fibrillation under the anticoagulant therapy of warfarin were allocated into 2 groups: 67 patients in group(international normalized ratio 1.6～2.4) ; 50 patients in group(INR 2.5～3.5). the incidence rates of complications with thromboembolism and adverse effects with hemorrhage etc were observed. Results: The annual rate of thromboembolism in group(INR 1.6～2.4) is 0.75%, in group(INR 2.5～3.5) is 0, there is no significant difference between 2 groups(P>0.05). 94% adverse effects in 2 groups are hemorrhage, the annual rate of hemorrhage in group(1.6～2.4) is 6.9%, in group(2.5～3.5) is 16.2%, it differ significantly (P<0.005), but all the hemorrhage cases are not serious. Other adverse effects includes skin rash and digestive symptoms. Conclusions: When INR between 1.6 to 3.5, the warfarin treatment can obviously cut down the thromboembolism rate in patients with nonvalvular artial fibrillation and the treatment is safe. There is some risk for thromboembolism when INR between 1.6 to 2.4, and some risk for hemorrhage when INR between 2.5 to 3.5.更多还原